lovastatin has been researched along with Cancer of Head in 7 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 1 (14.29) | 18.2507 |
| 2000's | 3 (42.86) | 29.6817 |
| 2010's | 2 (28.57) | 24.3611 |
| 2020's | 1 (14.29) | 2.80 |
| Authors | Studies |
|---|---|
| Buchwald, ZS; Burnham, AJ; Kansal, V; Kinney, BLC; Lesinski, GB; Paulos, C; Saba, NF; Schmitt, NC | 1 |
| Corsten, M; Dimitroulakos, J; Gorn-Hondermann, I; Johnson-Obeseki, S; Ma, L; Niknejad, N; Zahr, S | 1 |
| Bradbury, PA; Dimitroulakos, J; Ding, K; Goss, G; Le Francois, BG; Zhao, TT | 1 |
| Dimitroulakos, J; Goss, G; Lorimer, IA; Mantha, AJ; McFee, KE; Niknejad, N | 1 |
| Chen, E; Chin, S; Dimitroulakos, J; Irish, J; Kamel-Reid, S; Knox, JJ; LaFramboise, S; Moore, MJ; Oza, AM; Siu, LL | 1 |
| Dimitroulakos, J; Morley, M; Niknejad, N | 1 |
| Hamilton, AD; Qian, Y; Sebti, SM; Sun, J; Vogt, A | 1 |
1 trial(s) available for lovastatin and Cancer of Head
| Article | Year |
|---|---|
A Phase I trial of prolonged administration of lovastatin in patients with recurrent or metastatic squamous cell carcinoma of the head and neck or of the cervix.
Topics: Adult; Aged; Carcinoma, Squamous Cell; Female; Head and Neck Neoplasms; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Lovastatin; Male; Middle Aged; Neoplasm Recurrence, Local; Treatment Outcome; Uterine Cervical Neoplasms | 2005 |
6 other study(ies) available for lovastatin and Cancer of Head
| Article | Year |
|---|---|
Statin drugs enhance responses to immune checkpoint blockade in head and neck cancer models.
Topics: Animals; Head and Neck Neoplasms; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Immune Checkpoint Inhibitors; Lovastatin; Mice; Simvastatin; Squamous Cell Carcinoma of Head and Neck | 2023 |
Lovastatin-induced apoptosis is mediated by activating transcription factor 3 and enhanced in combination with salubrinal.
Topics: Activating Transcription Factor 3; Animals; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Blotting, Western; Breast Neoplasms; Carcinoma, Squamous Cell; Cell Membrane Permeability; Cell Proliferation; Cinnamates; Drug Resistance, Neoplasm; Drug Synergism; Embryo, Mammalian; Eukaryotic Initiation Factor-2; Female; Fibroblasts; Flow Cytometry; Head and Neck Neoplasms; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Immunoenzyme Techniques; Lovastatin; Male; Membrane Potential, Mitochondrial; Mice; Phosphorylation; Prostatic Neoplasms; Real-Time Polymerase Chain Reaction; Reverse Transcriptase Polymerase Chain Reaction; RNA, Messenger; RNA, Small Interfering; Thiourea; Tumor Cells, Cultured | 2014 |
Lovastatin inhibits EGFR dimerization and AKT activation in squamous cell carcinoma cells: potential regulation by targeting rho proteins.
Topics: Amides; Animals; Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; Cell Line, Tumor; Cytoskeleton; Dimerization; Drug Interactions; Enzyme Activation; ErbB Receptors; Head and Neck Neoplasms; Humans; Lovastatin; Lung Neoplasms; Mice; NIH 3T3 Cells; Polyisoprenyl Phosphates; Proto-Oncogene Proteins c-akt; Pyridines; rho-Associated Kinases; Signal Transduction | 2010 |
Epidermal growth factor receptor-targeted therapy potentiates lovastatin-induced apoptosis in head and neck squamous cell carcinoma cells.
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Carcinoma, Squamous Cell; Cell Line, Tumor; Cycloheximide; Dactinomycin; Drug Delivery Systems; ErbB Receptors; Head and Neck Neoplasms; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Lovastatin; Protein-Tyrosine Kinases | 2003 |
Activation of the integrated stress response regulates lovastatin-induced apoptosis.
Topics: Animals; Antineoplastic Agents; Apoptosis; Carcinoma, Squamous Cell; Cell Line, Tumor; Drug Screening Assays, Antitumor; Eukaryotic Initiation Factor-2; Fibroblasts; Head and Neck Neoplasms; Humans; Lovastatin; Mevalonic Acid; Mice; Models, Biological; Phosphorylation; Prodrugs | 2007 |
The geranylgeranyltransferase-I inhibitor GGTI-298 arrests human tumor cells in G0/G1 and induces p21(WAF1/CIP1/SDI1) in a p53-independent manner.
Topics: Alkyl and Aryl Transferases; Benzamides; Breast Neoplasms; Cell Cycle; Cells, Cultured; Cyclin-Dependent Kinase Inhibitor p21; Cyclins; Enzyme Inhibitors; Female; Fibrosarcoma; G1 Phase; Head and Neck Neoplasms; Humans; Lovastatin; Methionine; Oligopeptides; Pancreatic Neoplasms; Protein Prenylation; Resting Phase, Cell Cycle; Tumor Suppressor Protein p53; Urinary Bladder Neoplasms | 1997 |